Rhythm Pharmaceuticals RYTM
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Rhythm Pharmaceuticals (RYTM) Business Model and Operations Summary
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Key Insights
Rhythm Pharmaceuticals (RYTM) Core Market Data and Business Metrics
Latest Closing Price
$50Market Cap
$3.20 BillionPrice-Earnings Ratio
-11.52Total Outstanding Shares
63.22 Million SharesTotal Employees
283Dividend
No dividendIPO Date
October 5, 2017SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
222 Berkeley Street, Boston, MA, 02116
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $191.24 Million |
| Net Cash Flow | $29.19 Million |
| Net Cash Flow From Investing Activities | $-48.17 Million |
| Net Cash Flow From Operating Activities | $-113.88 Million |
| Net Cash Flow, Continuing | $29.19 Million |
| Net Cash Flow From Operating Activities, Continuing | $-113.88 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Benefits Costs and Expenses | $390.38 Million |
| Revenues | $130.13 Million |
| Operating Income/Loss | $-265.50 Million |
| Diluted Earnings Per Share | $-4.34 |
| Diluted Average Shares | $61.00 Million |
| Net Income/Loss Attributable To Parent | $-260.60 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-264.75 Million |
| Other Comprehensive Income/Loss | $-4.14 Million |
| Comprehensive Income/Loss Attributable To Parent | $-264.75 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Accounts Payable | $12.33 Million |
| Noncurrent Assets | $18.07 Million |
| Equity Attributable To Parent | $21.73 Million |
| Inventory | $18.74 Million |
| Equity | $21.73 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||